Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for ADC-induced neurotoxicity
NCT06551051Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duloxetine in peripheral neuropathy, sponsored by Fudan University. Primary endpoint: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity subscale at Day 36. Started Aug 2024; status: recruiting.
02
Drugs
duloxetine
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT06551051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551051.